Cargando…

Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus

Most viral diseases, with the exception of those caused by human immunodeficiency virus, are self-limited illnesses that do not require specific antiviral therapy. The currently available antiviral drugs target 3 main groups of viruses: herpes, hepatitis, and influenza viruses. With the exception of...

Descripción completa

Detalles Bibliográficos
Autor principal: Razonable, Raymund R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mayo Foundation for Medical Education and Research 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3184032/
https://www.ncbi.nlm.nih.gov/pubmed/21964179
http://dx.doi.org/10.4065/mcp.2011.0309
_version_ 1782213044352319488
author Razonable, Raymund R.
author_facet Razonable, Raymund R.
author_sort Razonable, Raymund R.
collection PubMed
description Most viral diseases, with the exception of those caused by human immunodeficiency virus, are self-limited illnesses that do not require specific antiviral therapy. The currently available antiviral drugs target 3 main groups of viruses: herpes, hepatitis, and influenza viruses. With the exception of the antisense molecule fomivirsen, all antiherpes drugs inhibit viral replication by serving as competitive substrates for viral DNA polymerase. Drugs for the treatment of influenza inhibit the ion channel M(2) protein or the enzyme neuraminidase. Combination therapy with Interferon-α and ribavirin remains the backbone treatment for chronic hepatitis C; the addition of serine protease inhibitors improves the treatment outcome of patients infected with hepatitis C virus genotype 1. Chronic hepatitis B can be treated with interferon or a combination of nucleos(t)ide analogues. Notably, almost all the nucleos(t) ide analogues for the treatment of chronic hepatitis B possess anti–human immunodeficiency virus properties, and they inhibit replication of hepatitis B virus by serving as competitive substrates for its DNA polymerase. Some antiviral drugs possess multiple potential clinical applications, such as ribavirin for the treatment of chronic hepatitis C and respiratory syncytial virus and cidofovir for the treatment of cytomegalovirus and other DNA viruses. Drug resistance is an emerging threat to the clinical utility of antiviral drugs. The major mechanisms for drug resistance are mutations in the viral DNA polymerase gene or in genes that encode for the viral kinases required for the activation of certain drugs such as acyclovir and ganciclovir. Widespread antiviral resistance has limited the clinical utility of M(2) inhibitors for the prevention and treatment of influenza infections. This article provides an overview of clinically available antiviral drugs for the primary care physician, with a special focus on pharmacology, clinical uses, and adverse effects.
format Online
Article
Text
id pubmed-3184032
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Mayo Foundation for Medical Education and Research
record_format MEDLINE/PubMed
spelling pubmed-31840322012-04-01 Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus Razonable, Raymund R. Mayo Clin Proc Symposium on Antimicrobial Therapy Most viral diseases, with the exception of those caused by human immunodeficiency virus, are self-limited illnesses that do not require specific antiviral therapy. The currently available antiviral drugs target 3 main groups of viruses: herpes, hepatitis, and influenza viruses. With the exception of the antisense molecule fomivirsen, all antiherpes drugs inhibit viral replication by serving as competitive substrates for viral DNA polymerase. Drugs for the treatment of influenza inhibit the ion channel M(2) protein or the enzyme neuraminidase. Combination therapy with Interferon-α and ribavirin remains the backbone treatment for chronic hepatitis C; the addition of serine protease inhibitors improves the treatment outcome of patients infected with hepatitis C virus genotype 1. Chronic hepatitis B can be treated with interferon or a combination of nucleos(t)ide analogues. Notably, almost all the nucleos(t) ide analogues for the treatment of chronic hepatitis B possess anti–human immunodeficiency virus properties, and they inhibit replication of hepatitis B virus by serving as competitive substrates for its DNA polymerase. Some antiviral drugs possess multiple potential clinical applications, such as ribavirin for the treatment of chronic hepatitis C and respiratory syncytial virus and cidofovir for the treatment of cytomegalovirus and other DNA viruses. Drug resistance is an emerging threat to the clinical utility of antiviral drugs. The major mechanisms for drug resistance are mutations in the viral DNA polymerase gene or in genes that encode for the viral kinases required for the activation of certain drugs such as acyclovir and ganciclovir. Widespread antiviral resistance has limited the clinical utility of M(2) inhibitors for the prevention and treatment of influenza infections. This article provides an overview of clinically available antiviral drugs for the primary care physician, with a special focus on pharmacology, clinical uses, and adverse effects. Mayo Foundation for Medical Education and Research 2011-10 /pmc/articles/PMC3184032/ /pubmed/21964179 http://dx.doi.org/10.4065/mcp.2011.0309 Text en © 2011 Mayo Foundation for Medical Education and Research
spellingShingle Symposium on Antimicrobial Therapy
Razonable, Raymund R.
Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus
title Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus
title_full Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus
title_fullStr Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus
title_full_unstemmed Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus
title_short Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus
title_sort antiviral drugs for viruses other than human immunodeficiency virus
topic Symposium on Antimicrobial Therapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3184032/
https://www.ncbi.nlm.nih.gov/pubmed/21964179
http://dx.doi.org/10.4065/mcp.2011.0309
work_keys_str_mv AT razonableraymundr antiviraldrugsforvirusesotherthanhumanimmunodeficiencyvirus